紫杉醇脂质体联合顺铂同步放疗对老年宫颈癌有较好疗效

本研究将178例具有危险因素的老年宫颈癌术后患者随机分为研究组和对照组各89例,对照组给予紫杉醇联合顺铂同步放化疗方案,研究组给予紫杉醇脂质体联合顺铂同步放化疗方案,观察2组患者治疗期间的毒副反应及1年、2年、3年生存率、局部复发率和远处转移率,以期探讨老年宫颈癌患者术后不同化疗方案联合同步放疗的有效性和安全性。研究结果表明:研究组骨髓抑制、消化道反应、肝肾功能异常、脱发发生率低于对照组(p<0.05);研究组1年、2年、3年生存率与对照组相比较均无统计学差异(p>0.05);研究组与对照组1年、2年、3年局部复发率和远处转移率相比较差异均无统计学意义(p>0.05)。本研究初步结论认为,老年宫颈癌患者术后采用紫杉醇脂质体联合顺铂同步放化疗方案更为安全有效,采用紫杉醇脂质体代替紫杉醇注射液值得在临床推广应用。

Better Effect of Concurrent Chemoradiotherapy of Paclitaxel Liposome Combined with Cisplatin on Elderly Patients with Cervical Cancer

This research selected 178 elderly postoperatives patients of cervical cancer who were randomly divided into the study group and control group with 89 cases each group. The control group was treated with concurrent chemoradiotherapy with paclitaxel and cisplatin, while the study group was treated with concurrent chemoradiotherapy of paclitaxel liposome combined with cisplatin. In order to study the efficacy and safety combined with synchronous radiotherapy in elderly patients with postoperative cervical cancer, the study observed the toxic and adverse reactions during treatment, and survival rate, local recurrence rate, distant metastasis rate at 1 year, 2 years and 3 years of these2 groups of patients. The results showed that the incidence rates of bone marrow suppression, gastrointestinal reaction,liver and kidney dysfunction, hair loss of study group were significantly lower than those of control group(p<0.05).There was no statistic difference in survival rate at 1 year, 2 years and 3 years between two groups(p>0.05). There was no statistic difference in local recurrence rate, distant metastasis rate at 1 year, 2 years and 3 years between two groups(p>0.05). Our preliminary conclusion suggested that paclitaxel liposome combined with cisplatin concurrent chemoradiotherapy should be more safe and effective for the elderly patients with cervical cancer after surgery, and the use of paclitaxel liposome instead of paclitaxel injection might be worthy of clinical application.